All lobbying filings

CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY

Lobbying for CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY · nonprofit organization

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 12, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

New York

Official filing document

Lobbyists on this filing 1

AZHAR MAJEED

Previously held: Director of Government Affairs and Policy

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Science/Technology

CFI's Office of Public Policy lobbied against S. 4692, the "Homeopathic Drug Product Safety, Quality, and Transparency Act." This legislation would allow lax federal regulation of the homeopathy industry, using homeopathy-specific standards set by the industry for safety and efficacy. While homeopathy groups favor this approach, evidence shows that these products are not safe for American consumers and patients. The Office of Public Policy continues to raise awareness among Congressional offices regarding this public health issue.

Bills named in this filing 1

S. 4692
Homeopathic Drug Product Safety, Quality, and Transparency Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.